In order to determine the methylation status of individual CpG sites in the NPC samples relative to the non-malignant control biopsies, the detailed methylation status of the UBE2L6 promoter region −204 to +156 bp, containing 42 CpG sites, relative to the translation start site, was determined by bisulphite genomic sequencing. Here, UBE2L6 is linked to nasopharyngeal carcinoma.